SEARCH:   Advanced

Blood, 15 April 2006, Vol. 107, No. 8, pp. 3058-3064. Prepublished online as a Blood First Edition Paper on December 29, 2005; DOI 10.1182/blood-2005-04-1570. This Article Full Text (PDF) All Versions of this Article: 2005-04-1570v1 107/8/3058    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Glass, B. Articles by Schmitz, N. Search for Related Content PubMed PubMed Citation Articles by Glass, B. Articles by Schmitz, N. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 18, 2005 Accepted November 14, 2005 Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem-cell transplantation for primary treatment of aggressive high-risk non-hodgkin's lymphoma Bertram Glass*, Marita Kloess, Martin Bentz, Gunter Schlimok, Wolfgang E Berdel, Alfred Feller, Lorenz Trumper, Markus Loeffler, Michael Pfreundschuh, and Norbert Schmitz Department of Hematology and Oncology, University Hospital Gottingen, Gottingen, Germany Institute of Medical Informatics, Statistics, and Epidemiology, University of Leipzig, Leipzig, Germany Department of Hematology and Oncology, Community Hospital Karlsruhe, Karlsruhe, Germany Department of Internal Medicine II, Klinikum Augsburg, Augsburg, Germany Department of Internal Medicine A, University of Munster, Munster, Germany Institute of Pathology, University of Schleswig-Holstein, Lubeck, Germany Hospital of Medicine, Saarland University Medical School, Homburg, Germany Department of Hematology, AK St. Georg, Hamburg, Germany * Corresponding author; email: b.glass{at}med.uni-goettingen.de. Feasibility, safety and efficacy of a four-course high-dose chemotherapy (HDT) protocol including autologous stem cell transplantation (SCT) after courses 2, 3 and 4 was investigated in 110 patients with primary diagnosis of aggressive NHL (aNHL), age 18 to 60 years and LDH above normal. At dose level (DL) 1, course 1 consisted of cyclophosphamide 1500 mg/m2, padriamycin 70 mg/m2, vincristine 2 mg, etoposide 450 mg/m2, and prednisone 500 mg. With courses 2 and 3 cyclophosphamide and etoposide were escalated to 4500 mg/m2 and 600 mg/m2, respectively. In course 4 cyclophosphamide and etoposide were given at 6000 mg/m2 and 1000 mg/m2, respectively. At DL 2 etoposide was further increased to 600, 960, 960 and 1480 mg/m2 with courses 1 to 4, respectively. Therapy as per protocol was completed by 81.8% of patients. Overall survival at 5 years was 67.2%, freedom from treatment failure (FFTF) was 62.1% and treatment related mortality was 4.5%. There was a trend to better FFTF at DL2 compared to DL1 (66.9% vs 54.2%). Repetitive HDT with escalated CHOP + etoposide is feasible and effective treatment of patients with aNHL. Dose level 2 of this therapy is used in an ongoing phase III study. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. Haioun, N. Mounier, J. F. Emile, D. Ranta, B. Coiffier, H. Tilly, C. Recher, C. Ferme, J. Gabarre, R. Herbrecht, et al. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma Ann. Onc., December 1, 2009; 20(12): 1985 - 1992. [Abstract] [Full Text] [PDF] M. Nickelsen, M. Ziepert, S. Zeynalova, B. Glass, B. Metzner, M. Leithaeuser, H. K. Mueller-Hermelink, M. Pfreundschuh, and N. Schmitz High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) Ann. Onc., December 1, 2009; 20(12): 1977 - 1984. [Abstract] [Full Text] [PDF] U. Vitolo, A. Chiappella, E. Angelucci, G. Rossi, A. M. Liberati, M. G. Cabras, B. Botto, G. Ciccone, G. Gaidano, L. Falchi, et al. Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study Haematologica, September 1, 2009; 94(9): 1250 - 1258. [Abstract] [Full Text] [PDF] J. Haessler, J. D. Shaughnessy Jr., F. Zhan, J. Crowley, J. Epstein, F. van Rhee, E. Anaissie, M. Pineda-Roman, M. Zangari, K. Hollmig, et al. Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling Clin. Cancer Res., December 1, 2007; 13(23): 7073 - 7079. [Abstract] [Full Text] [PDF] N. Schmitz, P. Dreger, B. Glass, and A. Sureda Allogeneic transplantation in lymphoma: current status Haematologica, November 1, 2007; 92(11): 1533 - 1548. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020